Are too few women being offered breast-conserving treatment?
Two new studies presented at the ESMO 2012 Congress in Vienna, Austria show how improvements in breast cancer treatments are making it possible for more women to conserve their breasts following...
View ArticleNew hope for taming triple-negative breast cancer
Disease-free survival is short-lived for women with triple-negative breast cancer—a form of the disease that doesn't respond to hormone drugs and becomes resistant to chemotherapy. Thankfully, a...
View ArticleAbraxane approved to treat advanced lung cancer
(HealthDay)—Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration—in combination with the drug carboplatin—to treat advanced or spreading non-small cell lung...
View ArticleResearchers develop new drug delivery system for bladder cancer using...
A team of UC Davis scientists has shown in experimental mouse models that a new drug delivery system allows for administration of three times the maximum tolerated dose of a standard drug therapy for...
View ArticleCancer drug improves survival in patients with metastatic melanoma
(Medical Xpress)—Results of a University of Arizona Cancer Center's scientist-led clinical trial show that a drug already approved for breast and lung cancer improved progression-free survival in...
View ArticleOptimal dose suggested for dasatinib in ovarian cancer
(HealthDay)—A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian...
View ArticleTwo-drug combination may slow deadly thyroid cancer
A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational...
View ArticleStudy shows drug combination extends pancreatic cancer patient survival
A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients...
View ArticleAdding elesclomol to paclitaxel for advanced melanoma studied
(HealthDay)—Lactate dehydrogenase (LDH) levels may be predictive of success in treating chemotherapy-naive patients with advanced melanoma with a combination of elesclomol plus paclitaxel, according to...
View ArticleMedication duloxetine helps reduce pain from chemotherapy
Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according...
View ArticleParagazole excels in preclinical models of triple-negative breast cancer
Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes...
View ArticleScientists develop simple blood test to track tumour evolution in cancer...
By tracking changes in patients' blood, Cambridge scientists have created a new way of looking at how tumours evolve in real-time and develop drug resistance. The research was published in the print...
View ArticleWhole genome or exome sequencing: An individual insight
Focusing on parts rather than the whole, when it comes to genome sequencing, might be extremely useful, finds research in BioMed Central's open access journal Genome Medicine. The research compares...
View ArticleTeam successfully completes fisrt clinical trial on HER-2-negative breast...
The experimental drug nintedanib, combined with standard chemotherapy with paclitaxel, causes a total remission of tumours in 50% of patients suffering from early HER-2- negative breast cancer, the...
View ArticleExperimental drug combined with standard chemo may shrink ovarian cancers
Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer...
View ArticleResearchers hope to use artificial intelligence to improve breast cancer...
Western University researchers are working on a way to use artificial intelligence to predict a patient's response to two common chemotherapy medications used to treat breast cancer - paclitaxel and...
View ArticleOne-two punch of palbociclib and paclitaxel shows promise against advanced...
Combining the new breast cancer drug palbociclib with paclitaxel (Taxol) shrank tumors in nearly half of patient with estrogen-receptor (ER) positive breast cancer, according to new research from the...
View ArticleNeratinib plus paclitaxel vs. trastuzumab plus paclitaxel in breast cancer
While neratinib plus paclitaxel was not superior to trastuzumab plus paclitaxel as first-line treatment for ERBB2-positive metastatic breast cancer in terms of progression-free survival, the...
View ArticleEvidence show new drug combination may improve outcomes for women with...
Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more...
View ArticleLow doses of common cancer drug may promote cancer spread
New research indicates that paclitaxel, which is the most commonly used chemotherapy for breast cancer, suppresses tumors when given at a certain dosage, but at low doses, it actually promotes cancer...
View Article